Nora Therapeutics, Inc.
Therapeutics for IVF failure and recurrent pregnancy loss
About Nora Therapeutics, Inc.
Nora Therapeutics was a biopharmaceutical company focused on developing treatments for unmet needs in reproductive medicine, specifically addressing in vitro fertilization (IVF) failure and recurrent pregnancy loss. The company was founded in 2007 by Chris McClain and was headquartered in Palo Alto, California.
The company's lead product candidate was NT100, a biologic agent designed to be similar to a naturally occurring protein in the female reproductive tract. The goal of NT100 was to improve the chances of embryo implantation and maintain pregnancy by optimizing maternal-fetal immune tolerance. Nora Therapeutics conducted Phase 2 clinical trials for NT100, including the THRIVE-IVF trial for women with a history of failed IVF cycles and the RESPONSE trial for women with unexplained recurrent pregnancy loss. The company's business model was centered on the research and development of these specialized therapeutics with the aim of bringing an FDA-approved treatment to a market with few options.
Nora Therapeutics was venture-backed, raising a total of $37.8 million over five funding rounds from investors including Novo Holdings, Vivo Capital, Prospect Venture Partners, Rho Ventures, and Burrill & Company. A significant Series B financing round in April 2014 raised $18 million to advance the clinical trials for NT100. Despite its efforts in clinical development and securing funding, Nora Therapeutics ultimately went out of business, with its status listed as closed around January 2017.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Employees
- 2
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Fertility, Pregnancy, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2015 | — | — | Undisclosed | — |
| SERIES B✓Equity / VC | Apr 2014 | $18M | $72M | Rho Ventures · Burrill · Prospect Venture Partners · Novo Holdings | — |
Growth signals
Latest recorded traffic for Nora Therapeutics, Inc. is 0 monthly website visits. Nora Therapeutics, Inc.'s team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nora Therapeutics, Inc. in the Palo Alto ecosystem
The Nora Therapeutics, Inc. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Novo Seeds
Rho Ventures
Burrill- PPProspect Venture Partners
Novo Holdings
Vivo Capital
Other known investors1 additional known investor
Rho Canada Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nora Therapeutics, Inc. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nora Therapeutics, Inc.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









